The role of fibroblast APC mutation in carcinogenesis is not clear. Apc+/− colon fibroblasts have been previously characterized: however, little is known about their behavior at very early-stage of colon carcinogenesis. We cultured colon mucosa fibroblasts (PCF, Apc+/−) of Pirc rats (F344/NTac-Apcam1137) at an early stage of tumorigenesis, in absence of preneoplastic lesions, and of age-matched wt (WCF): DNA damage levels, inflammatory phenotype and the expression of known markers of CAFs were analyzed. The latter were also assessed by microarray analysis on colon normal mucosa of Pirc and wt animals. PCF exhibited higher proliferative rates (P <.001) and delayed replicative senescence onset (P <.05) compared to WCF, along with a lower level of oxidative DNA damage (P <.05). Furthermore, a constitutively higher expression of COX-2 and sensitivity to inflammatory stimuli was found in PCF compared to WCF (P <.05), accompanied by higher invasive capability (P <.05) and presence of cytoplasmic chromatin foci (cytoplasmic chromatin foci, P <.05). However, they neither expressed CAFs markers (α-SMA, IL-6) nor responded to CAFs activating stimuli (TGF-β). Accordingly, CAFs markers and activating stimuli resulted down-regulated in Pirc normal mucosa compared to wt, whereas DNA damage response and tolerance pathways were overexpressed. These data show for the first time that a proliferative and inflammatory phenotype characterizes Apc+/− colon fibroblasts since very early stages of colon tumorigenesis, and indicate a role of Apc mutation in driving fibroblast phenotypic alterations that could support the establishment of a protumorigenic environment. Early pharmacological targeting of these dysfunctions might impact on tumor prevention in FAP patients.

Colon fibroblasts from Pirc rats (F344/NTac-Apcam1137) exhibit a proliferative and inflammatory phenotype that could support early stages of colon carcinogenesis / Tortora K.; Margheri F.; Luceri C.; Mocali A.; Ristori S.; Magnelli L.; Caderni G.; Giovannelli L.. - In: INTERNATIONAL JOURNAL OF CANCER. - ISSN 0020-7136. - ELETTRONICO. - 150:(2022), pp. 362-373. [10.1002/ijc.33796]

Colon fibroblasts from Pirc rats (F344/NTac-Apcam1137) exhibit a proliferative and inflammatory phenotype that could support early stages of colon carcinogenesis

Tortora K.;Margheri F.;Luceri C.;Mocali A.;Ristori S.;Magnelli L.;Caderni G.;Giovannelli L.
2022

Abstract

The role of fibroblast APC mutation in carcinogenesis is not clear. Apc+/− colon fibroblasts have been previously characterized: however, little is known about their behavior at very early-stage of colon carcinogenesis. We cultured colon mucosa fibroblasts (PCF, Apc+/−) of Pirc rats (F344/NTac-Apcam1137) at an early stage of tumorigenesis, in absence of preneoplastic lesions, and of age-matched wt (WCF): DNA damage levels, inflammatory phenotype and the expression of known markers of CAFs were analyzed. The latter were also assessed by microarray analysis on colon normal mucosa of Pirc and wt animals. PCF exhibited higher proliferative rates (P <.001) and delayed replicative senescence onset (P <.05) compared to WCF, along with a lower level of oxidative DNA damage (P <.05). Furthermore, a constitutively higher expression of COX-2 and sensitivity to inflammatory stimuli was found in PCF compared to WCF (P <.05), accompanied by higher invasive capability (P <.05) and presence of cytoplasmic chromatin foci (cytoplasmic chromatin foci, P <.05). However, they neither expressed CAFs markers (α-SMA, IL-6) nor responded to CAFs activating stimuli (TGF-β). Accordingly, CAFs markers and activating stimuli resulted down-regulated in Pirc normal mucosa compared to wt, whereas DNA damage response and tolerance pathways were overexpressed. These data show for the first time that a proliferative and inflammatory phenotype characterizes Apc+/− colon fibroblasts since very early stages of colon tumorigenesis, and indicate a role of Apc mutation in driving fibroblast phenotypic alterations that could support the establishment of a protumorigenic environment. Early pharmacological targeting of these dysfunctions might impact on tumor prevention in FAP patients.
150
362
373
Tortora K.; Margheri F.; Luceri C.; Mocali A.; Ristori S.; Magnelli L.; Caderni G.; Giovannelli L.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1253446
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact